Characterization of Nkx3.2 DNA Binding Specificity and Its Requirement for Somitic Chondrogenesis*

Dae-Won Kim {ddagger}, Hervé Kempf §, Raymond E. Chen and Andrew B. Lassar 

From the Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115

Received for publication, February 11, 2003 , and in revised form, April 14, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
We have previously shown that Nkx3.2, a member of the NK class of homeoproteins, functions as a transcriptional repressor to promote somitic chondrogenesis. However, it has not been addressed whether Nkx3.2 can bind to DNA in a sequence-specific manner and whether DNA binding by Nkx3.2 is required for its biological activity. In this work, we employed a DNA binding site selection assay, which identified TAAGTG as a high affinity Nkx3.2 binding sequence. Sequence-specific binding of Nkx3.2 to the TAAGTG motif in vitro was confirmed by electrophoretic mobility shift assays, and mutagenesis of this sequence revealed that HRAGTG (where H represents A, C, or T, and R represents A or G) comprises the consensus DNA binding site for Nkx3.2. Consistent with these findings, the expression of a reporter gene containing reiterated Nkx3.2 binding sites was repressed in vivo by Nkx3.2 co-expression. In addition, we have generated a DNA nonbinding point mutant of Nkx3.2 (Nkx3.2-N200Q), which contains an asparagine to glutamine missense mutation in the homeodomain. Interestingly, despite being defective in DNA binding, Nkx3.2-N200Q still retains its intrinsic transcriptional repressor function. Finally, we demonstrate that unlike wild-type Nkx3.2, Nkx3.2-N200Q is unable to activate the chondrocyte differentiation program in somitic mesoderm, indicating that DNA binding by Nkx3.2 is critical for this factor to induce somitic chondrogenesis.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Endochondral ossification, which accounts for the majority of vertebrate skeletal formation, begins with chondrogenesis, in which a cartilaginous template is established prior to replacement by mature bone tissue (1). The cartilage of the axial skeleton originates from somites, paired blocks of mesodermal tissue symmetrically flanking the central vertebrate axis (1). Whereas the dorsal domain of each somite, the dermomyotome, is a progenitor tissue for skeletal muscle and dermis, the ventral domain of the somite, the sclerotome, differentiates into the cartilage template of the vertebrae and ribs (2, 3). Signals from the notochord are crucial for the induction of the sclerotome and subsequent formation of axial cartilage (4). Sonic Hedgehog (Shh),1 a secreted molecule expressed in both the notochord and floor plate of the neural tube, has been shown to be required for somitic chondrogenesis (57). In addition to Shh, bone morphogenetic proteins (BMPs) also play an important role in axial cartilage differentiation (811). However, it is currently unclear how BMP signal transduction pathways act to promote somitic chondrogenesis.

Nkx3.2, the vertebrate homologue of Drosophila bagpipe (NK3), is a member of the NK family of homeoproteins, which have been shown to be involved in cell fate specification and the differentiation of various organs (12, 13). Nkx3.2 is initially expressed in the sclerotomal portion of the somites, and its expression is maintained in developing cartilage (14). Nkx3.2-deficient mice lack the ventral medial region of their vertebrae (1517), indicating a crucial role for this transcription factor to promote somitic chondrogenesis. We have previously shown that Shh signals can induce expression of Nkx3.2 in paraxial mesoderm and that forced expression of Nkx3.2 can activate somitic chondrogenesis in the absence of Shh signals (8, 10). Our prior findings also indicate that induction of chondrogenesis by Nkx3.2 requires both its transcriptional repressor activity and the presence of BMP signals (10). However, it has not been examined whether Nkx3.2 can bind to a specific DNA sequence(s) and, more importantly, whether the DNA binding activity of Nkx3.2 is required for its biological function. In this work, using a binding site selection assay, we both identify a high affinity DNA binding sequence for Nkx3.2 and determine the consensus DNA binding site for this transcription factor. Furthermore, we demonstrate that Nkx3.2 can bind to DNA in a sequence-specific manner both in vitro and in vivo and that the DNA binding activity of Nkx3.2 is essential for this factor to promote somitic chondrogenesis.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Biological Materials and Antibodies—Fertilized chicken eggs were obtained from SPAFAS. Recombinant human BMP4 protein was a generous gift from Genetics Institute. Anti-GST monoclonal antibody was purchased from Sigma.

Oligonucleotides—Oligonucleotides for cyclic amplification of sequence of target (CAST) were as follows: N15-random oligonucleotide, GAGTCCAGCGAATTCTGTCGN15GAGTCCTCGAGAGTGTCAAC; CAST top strand, GAGTCCAGCGAATTCTGTCG; CAST bottom strand, GTTGACACTCTCGAGGACTC. Oligonucleotides for EMSAs and reporter constructs were as follows: Nkx3.2 binding element (NBE) top strand, ACGAGGTACCTTACTTAAGTGGACGTGTCTTAAGTGGACGTAGCCTTAAGTGGACGTTGAACGCGTACTGT; NBE-m1 top strand, ACGAGGTACCTTACTTAGATGGACGTGTCTTAGATGGACGTAGCCTTAGATGGACG TTGAACGCGTACTGT; NBE-m2 top strand, ACGAGGTACCTTACTTAGGCGGACGTGTCTTAGGCGGACGTAGCCTTAGGCGGACGTTGAACGCGTACTGT; Nkx2.1 site top strand, ACGAGGTACCTTACTCAAGTGGACGTGTCTCAAGTGGACGTAGCCTCAAGTGGA CGTTGAACGCGTACTGT; Msx1 site top strand, ACGAGGTACCTTACTTAATTGGACGTGTCTTAATTGGACGTAGCCTTAATTGGACGTTGAACGCGTACTGT; Nkx3.1 site top strand, ACGAGGTACCTTACTTAAGTAGACGTGTCTTAAGTAGACGTAGCCTTAAGTAGACGTTGAACGCGTACTGT; bottom strand for all of the above top strands, ACAGTACGCGTTCAACGTC. Oligonucleotides for Nkx3.2-N200Q Mutagenesis were as follows: Nkx3.2 N terminus top strand, tttGGATCCatggccgtccgcggcggcggc; Nkx3.2 C terminus bottom strand, tttATCGATCActgcgtgccggcggccgcggc; N200Q top strand, gaagatctggttccagcAacgccgctacaaaacc; N200Q bottom strand, ggttttgtagcggcgtTgctggaaccagatcttc.

Plasmids and Molecular Cloning—To generate the pGEX-Nkx3.2-HA bacterial expression construct, the C-terminal HA-tagged Nkx3.2 insert in SLAX13 (10) was liberated with NcoI and XbaI and cloned into pGEX-NcoI, which contains an engineered NcoI site between the BamHI and EcoRI sites of pGEX-2TK (Amersham Biosciences). To create pCS2-Nkx3.2 and pCS2-Nkx3.2-VP16, the respective inserts in SLAX13 (10, 18) were liberated with a 5' Klenow-filled NcoI site and a 3' XbaI overhang and ligated into a linearized pCS2 empty vector with a 3' Klenow-filled BamHI site and a 5' XbaI overhang. To construct the NBE, NBE-m1, and NBE-m2 reporters, the respective double-stranded oligonucleotides (see "Oligonucleotides" for sequences) were digested with KpnI and MluI and cloned into pGL3P (Promega). Nkx3.2-N200Q cDNA was generated by in vitro PCR mutagenesis using primers described under "Oligonucleotides," and the PCR product was digested with NcoI to generate a 5' overhang and ligated into a linearized SLAX13 shuttle vector with 3' NcoI and 5' SmaI overhangs. For pGEX-Nkx3.2-N200Q and pCS2-Nkx3.2-N200Q, the inserts were liberated from SLAX13-Nkx3.2-N200Q and cloned into pGEX-NcoI or pCS2 exactly as described above for wild-type Nkx3.2. A GAL4-DBD empty vector, pSG424 (19), GAL4-Nkx3.2 expression plasmid (10) and 5X-GAL4-pGL3E luciferase reporter gene (20) have been previously described. To construct GAL4-Nkx3.2-N200Q, the Nkx3.2-N200Q insert in SLAX13 was liberated with a 5' Klenow-filled NcoI site and a 3' XbaI overhang and ligated into a linearized pSG424 empty vector with SmaI and XbaI. To generate RCAS(A)-Nkx3.2-N200Q, the Nkx3.2-N200Q insert in SLAX13 was transferred as a ClaI fragment into RCAS(A) (21). All constructs newly generated in this work were verified by DNA sequencing.

CAST—Recombinant GST-Nkx3.2-HA protein was bacterially expressed and affinity-purified using glutathione-agarose beads following the manufacturer's instructions provided by Amersham Biosciences. The affinity-purified GST-Nkx3.2-HA protein was then immunopurified by anti-HA immunoprecipitation in immunoprecipitation buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM dithiothreitol, and 0.5% Nonidet P-40). This double-purified GST-Nkx3.2-HA protein, immobilized on protein G-agarose beads, was used for the binding site selection assay. The CAST assay was carried out essentially as previously described with some modifications (22, 23). Briefly, 0.5 pmol of short double-stranded DNA containing a 15-bp random sequence flanked by 20-bp fixed sequences was incubated in DNA binding buffer (10 mM Tris (pH 7.5), 50 mM NaCl, 7.5 mM MgCl2, 1 mM EDTA, 5% glycerol, 5% sucrose, 0.1% Nonidet P-40, and 5 mg/ml bovine serum albumin) with 100 ng of double-purified GST-Nkx3.2-HA protein for 20 min at room temperature. Unbound DNAs were washed away with DNA binding buffer, and the bound DNA sequences were amplified by PCR for the next round. A total of five cycles of CAST were performed, and the final PCR product was cloned into the pCRII-TOPO vector using a TOPO-TA cloning kit (Invitrogen), and the cloned inserts were sequenced.

Electrophoretic Mobility Shift Assay (EMSA)—Binding reactions for EMSAs were done in 10 mM Tris (pH 7.5), 50 mM NaCl, 1.5 mM MgCl2, 2.5 mM dithiothreitol, 5% glycerol, 5 µg/ml poly(dI)-poly(dC), and 250 µg/ml bovine serum albumin. Reaction mixtures were incubated with various 32P-labeled probes (250,000 cpm/reaction). All of the EMSA probes were labeled by PCR using [{alpha}-32P]dCTP after annealing indicated top and bottom strand oligonucleotides described under "Oligonucleotides." If necessary, anti-GST antibody or the indicated cold competitors (25- or 100-fold excess) were preincubated before the addition of the various 32P-labeled probes. Binding reactions were electrophoresed through 5% polyacrylamide gels (39:1 acrylamide/bis) containing 2.5% glycerol in 0.5x TBE buffer at room temperature. The gel was then fixed, dried, and exposed to x-ray film.

Cell Culture and Reporter Assays—Murine NIH-3T3 fibroblasts were grown in Dulbecco's modified Eagle's medium with 10% fetal calf serum. For transient transfection, FuGENE6 from Roche Applied Science was used according to the manufacturer's instructions. Following the transfections, the cells were incubated for 40 h before harvest. For each transfection, 100 ng of reporter construct, 200 ng of the indicated expression plasmid, and 20 ng of pRL-TK normalization plasmid were used per single well of a 12-well plate. pCS2 empty vector was used to adjust total DNA amounts where necessary. Dual luciferase assays were carried out with total cell extracts as recommended by Promega. All transfection experiments were performed in duplicate, and results were normalized to the expression of the Renilla luciferase transfection control.

Chick Embryo Explant Culture, Retroviral Infection, and RT-PCR Analysis—Construction of RCAS(A)-Nkx3.2 (10) and RCAS(A)-Nkx3.2-N200Q (see "Plasmids and Molecular Cloning") viruses has been previously described. RCAS(A)-GFP was generously provided by Cliff Tabin. RCAS retroviruses were produced from chicken embryonic fibroblasts exactly as previously described (24). Dissection and culture of presomitic mesoderm (psm) explants was previously described (8, 10). BMP4 protein was added to a final concentration of 100 ng/ml on the second day of explant culture. For retroviral infection, each freshly dissected psm explant was placed into a droplet on a Petri dish consisting of 5 µl of culture medium and 5 µl of concentrated viral supernatant. This Petri dish was then placed on ice for 1 h before the explants were removed and embedded in collagen. RNA harvest and RT-PCR analyses of explants were carried out as described previously (8, 10).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Determination of Nkx3.2 Consensus DNA Binding Sequence by CAST—To define a consensus sequence for Nkx3.2 DNA binding, the CAST (also known as selected and amplified binding sequence, or SAAB) assay was employed as previously described (22, 23, 25, 26). Recombinant GST-Nkx3.2-HA protein was bacterially expressed and double-purified by GST purification and subsequent anti-HA antibody immunoprecipitation as described under "Experimental Procedures." SDS-PAGE and Coomassie Brilliant Blue staining verified purification of GST-Nkx3.2-HA to homogeneity (data not shown). This double-purified GST-Nkx3.2-HA protein, immobilized on protein G-agarose beads, was used to select high affinity binding sequences from a pool of oligonucleotides containing 15 random base pairs flanked by 20 base pairs of invariant sequence. Five cycles of CAST were performed, and the isolated high affinity binding sequences were cloned and sequenced. Negative control experiments using GST protein were carried out in parallel and did not result in any significant sequence selection.

Alignment of 24 selected sequences obtained from the Nkx3.2 CAST, along with the percentage occurrence of each base at each position, is shown in Fig. 1. Analysis revealed TAAGTG as both the most frequently observed hexanucleotide motif (Fig. 1, open boxed) and the consensus sequence for Nkx3.2 DNA binding. A significant preference for G nucleotides (50%) was also observed at the position immediately 3' to this TAAGTG sequence (Fig. 1), which we refer to as the Nkx3.2 binding element (NBE).



View larger version (34K):
[in this window]
[in a new window]
 
FIG. 1.
Nkx3.2 consensus DNA binding sequence. Selected and amplified Nkx3.2 binding sequences are aligned, and the most frequently observed TAAGTG sequence is shown in an open box. The percentage occurrence of each base at each position is also calculated and displayed.

 

Nkx3.2 Binds to the NBE in a Sequence-specific Manner—To confirm that Nkx3.2 can specifically bind to the NBE sequence in vitro, either purified GST or GST-Nkx3.2-HA recombinant proteins were incubated with 32P-labeled NBE probe (containing three reiterations of the sequence TAAGTG; 3x-TAAGTG) and analyzed by EMSA. Whereas GST failed to form a complex with the NBE probe, incubation of this probe with GST-Nkx3.2-HA resulted in a significant DNA-protein complex (Fig. 2A, compare lanes 2 and 3). Since complexes of three distinct electrophoretic mobilities were repeatedly observed following incubation of GST-Nkx3.2-HA with the NBE probe, which contained three reiterations of the TAAGTG sequence, we surmise that these distinct complexes may represent DNA-protein complexes containing different numbers of Nkx3.2 molecules bound to the DNA probe. To further confirm the identity of these shifted bands, anti-GST antibody was added to the binding reaction prior to electrophoresis. As expected, the addition of the anti-GST antibody decreased the mobility of the GST-Nkx3.2-NBE complex and diminished the total amount of this DNA-protein complex (Fig. 2A, lane 5).



View larger version (70K):
[in this window]
[in a new window]
 
FIG. 2.
Nkx3.2 can bind to the NBE in vitro. A, purified recombinant GST (lanes 2 and 4) or GST-Nkx3.2-HA (lanes 3 and 5) proteins were incubated with 32P-labeled NBE probes and processed for EMSA as described under "Experimental Procedures." Anti-GST antibody was preincubated with Nkx3.2 for 15 min on ice prior to the addition of the hot probes to the reactions (lanes 4 and 5). B, purified recombinant GST-Nkx3.2-HA protein was incubated with 32P-labeled NBE (lanes 1 and 2), NBE-m1 (lanes 3 and 4)or NBE-m2 (lanes 5 and 6) probes as indicated and processed for EMSA.

 

To determine whether Nkx3.2 binds to the NBE (TAAGTG) in a sequence-specific manner, the binding affinity of Nkx3.2 to either the "wild-type" NBE probe or two different mutant NBE probes, NBE-m1 (containing three reiterations of the sequence TAGATG) and NBE-m2 (containing three reiterations of the sequence TAGGCG), was analyzed. Purified recombinant GST-Nkx3.2-HA protein was incubated with 32P-labeled NBE, NBE-m1, or NBE-m2 probes, and each binding reaction was analyzed by EMSA. Whereas Nkx3.2 formed a stable complex with the NBE probe, it failed to form a complex with either the NBE-m1 or NBE-m2 probes (Fig. 2B, compare lanes 2, 4, and 6). These results confirm that Nkx3.2 binds to the NBE in a sequence-specific manner.

Nkx3.2 Binds to Various NBE-related Sequences but with Lower Affinities—The NBE (TAAGTG) sequence is very similar to the previously characterized consensus binding sites of other closely related homeoproteins (22, 23, 2729). For example, CAAGTG, TAAGTA, and TAATTG have been characterized as high affinity binding sequences for Nkx2.1 (28), Nkx3.1 (22), and Msx1/Hox7.1 (29), respectively. Accordingly, we investigated whether Nkx3.2 can also bind to these related consensus sequences. 32P-Labeled probes containing three reiterations of either TAAGTG (NBE), CAAGTG, TAATTG, or TAAGTA were incubated with increasing amounts of GST-Nkx3.2-HA (10, 40, or 100 ng), and binding of Nkx3.2 to the various sequences was analyzed by EMSA. Whereas the highest concentration of Nkx3.2 yielded a protein-DNA complex with each of these highly related sequences, Nkx3.2 bound to these non-NBE sequences with lower affinity relative to the NBE sequence, as indicated by the relatively lesser amount of shifted probe (Fig. 3A). Surprisingly, Nkx3.2 bound to the Nkx2.1 and Msx binding sites (CAAGTG and TAATTG, respectively) more avidly than to the DNA binding sequence (TAAGTA) of the highly related Nkx family member, Nkx3.1 (Fig. 3A, compare lanes 8, 12, and 16).



View larger version (52K):
[in this window]
[in a new window]
 
FIG. 3.
Nkx3.2 can bind to NBE-related sequences in vitro. A, 10 ng (lanes 2, 6, 10, and 14), 40 ng (lanes 3, 7, 11, and 15), or 100 ng (lanes 4, 8, 12, and 16) of purified recombinant GST-Nkx3.2-HA proteins were incubated with 32P-labeled probes containing either TAAGTG (NBE; lanes 1–4), CAAGTG (Nkx2.1 binding consensus; lanes 5–8), TAATTG (Msx1 binding consensus; lanes 9–12), or TAAGTA (Nkx3.1 binding consensus; lanes 13–16) and processed for EMSA. B, purified recombinant GST-Nkx3.2-HA was incubated with a 32P-labeled probe containing the NBE (TAAGTG) in either the absence (lane 2) or the presence of a 25- or 100-fold excess of unlabeled oligonucleotide competitors containing either TAAGTG (lanes 3 and 4), CAAGTG (lanes 5 and 6), TAATTG (lanes 7 and 8), or TAAGTA (lanes 9 and 10). Each reaction was analyzed by EMSA. C, purified recombinant GST-Nkx3.2-HA was incubated with a 32P-labeled oligonucleotide containing the NBE (TAAGTG) in either the absence (lane 2) or the presence of a 25- or 100-fold excess of unlabeled oligonucleotide containing either TAGGCG (NBE-m2; lanes 3 and 4) or TAAGTG (NBE; lanes 5 and 6) and processed for EMSA. D, purified GST-Nkx3.2-HA (lanes 2–18) was incubated with a 32P-labeled probe containing the NBE (TAAGTG) in either the absence (lane 2) or the presence of a 100-fold excess of unlabeled oligonucleotide containing either the NBE sequence or sequences differing from the NBE sequence at position 1 (lanes 3–6), position 2 (lanes 7–10), position 3 (lanes 11–14), or position 6 (lanes 15–18) and processed for EMSA. E, a consensus DNA binding sequence for Nkx3.2 is displayed.

 

To further confirm that Nkx3.2 binds with a higher affinity to the NBE relative to these other NBE-related sequences, the ability of these latter sequences to compete for NBE binding was explored. Purified GST-Nkx3.2-HA recombinant protein was incubated with the 32P-labeled NBE probe either in the absence or the presence of excess cold competitors, and the DNA/protein interaction was analyzed by EMSA. Nkx3.2 binding to the hot NBE probe (Fig. 3B, lane 2) was nearly completely extinguished in the presence of a 25-fold excess of cold NBE competitor (TAAGTG) (Fig. 3B, lane 3). In contrast, a 25-fold excess of cold competitors containing either CAAGTG, TAATTG, or TAAGTA sequences failed to compete for Nkx3.2 binding to the hot NBE probe as effectively as did the cold NBE probe (Fig. 3B, compare lanes 3, 5, 7, and 9). A 100-fold excess of all of the tested cold competitors successfully abolished Nkx3.2 DNA binding to the hot NBE probe (Fig. 3B, lanes 4, 6, 8, and 10). As a negative control, a competition EMSA using the NBE-m2 sequence as a cold competitor was carried out. Unlike the NBE or NBE-related sequences, neither a 25-fold nor a 100-fold excess of the cold NBE-m2 competitor significantly diminished Nkx3.2 binding to the hot NBE probe (Fig. 3C, compare lanes 2, 3, and 4). Together, these findings indicate that Nkx3.2 can also bind to various NBE-related sequences but with relatively lower affinities compared with the NBE sequence.

Systematic Characterization of Nkx3.2 Interaction with Sequences Deviating from the NBE—Because all Nkx3.2 DNA binding sites identified by the CAST technique contained A, G, and T at positions 3, 4, and 5, respectively (Fig. 1), it seems likely that these invariant residues are critical for interaction of Nkx3.2 with DNA. However, to systematically examine whether other nucleotides are necessary to support high affinity interaction of Nkx3.2 with the NBE sequence, we incubated Nkx3.2 with a hot NBE probe (TAAGTG) and added a 100-fold molar excess of oligonucleotides differing from the NBE sequence by a single base pair substitution in either the first, second, third, or sixth positions. We found that NBE-related oligonucleotides containing T in the first position competed slightly better for Nkx3.2 interaction than those containing either A or C in this position (Fig. 3D, lanes 3, 4, and 6), whereas oligonucleotides containing a G in this position failed to significantly compete for Nkx3.2 binding (Fig. 3D, lane 5). NBE-related oligonucleotides containing A in the second position competed slightly better for Nkx3.2 interaction than those containingaGin this position (Fig. 3D, lanes 7 and 9), whereas oligonucleotides containing either a C or T in this position failed to significantly compete for Nkx3.2 binding (Fig. 3D, lanes 8 and 10). Thus, Nkx3.2 can interact with sequences displaying some nucleotide variation at positions 1 and 2 of the NBE. In contrast, the binding site specificity for positions 3 and 6 is apparently invariant, since Nkx3.2 only bound to sequences containing A and G at these respective positions in the NBE (Fig. 3D, lanes 11–18). Consistent with our statistical analyses of the CAST results, as shown in Fig. 1, TAAGTG was clearly the strongest binding sequence for Nkx3.2. Furthermore, these findings allow us to more broadly define the Nkx3.2 DNA binding consensus as HRAGTG (where H represents A, C, or T, and R represents A or G; see Fig. 3E).

Nkx3.2 Can Regulate the Expression of an NBE-driven Reporter Gene in Vivo—Since we have shown that Nkx3.2 can bind to the NBE in vitro, we next examined whether Nkx3.2 can regulate the expression of an NBE-containing reporter gene in vivo. Either an empty vector (pCS2) or an expression vehicle encoding Nkx3.2 (pCS2-Nkx3.2) was co-transfected into NIH-3T3 murine fibroblasts with either the pGL3P luciferase control reporter (Promega) or the NBE-pGL3P luciferase reporter, which contains three NBE sites upstream of the SV40 basal promoter and luciferase reporter gene. Whereas Nkx3.2 only modestly repressed the expression of a co-transfected pGL3P luciferase reporter construct (~1.5-fold on average) (Fig. 4A, compare lanes 1 and 2), Nkx3.2 significantly repressed the expression of the NBE-pGL3P luciferase reporter by ~10-fold (Fig. 4A, compare lanes 3 and 4). These results suggest that Nkx3.2 can repress the expression of a reporter gene in vivo in an NBE-dependent manner. We surmise that the repression of the parental pGL3P reporter by Nkx3.2 may reflect low affinity binding sites for Nkx3.2 that are fortuitously present in this construct.



View larger version (30K):
[in this window]
[in a new window]
 
FIG. 4.
Nkx3.2 can bind to the NBE and regulate transcription in vivo. A, Nkx3.2 can repress expression of an NBE reporter. NIH-3T3 cells were co-transfected with either the pCS2 expression vector (lanes 1, 3, 5, and 7) or pCS2-Nkx3.2 (lanes 2, 4, 6, and 8) plus either the parental pGL3P control (lanes 1 and 2), NBE-pGL3P (lanes 3 and 4), NBE-m1-pGL3P (lanes 5 and 6), or NBE-m2-pGL3P (lanes 7 and 8) luciferase reporters. 40 h post-transfection, cell extracts were made and assayed for luciferase activity. B, a reverse function form of Nkx3.2, Nkx3.2-VP16, can activate expression of an NBE reporter. Either pCS2 empty vector (lane 1) or expression vehicles encoding Nkx3.2 (lane 2) or Nkx3.2-VP16 (lane 3) were co-transfected into NIH-3T3 cells along with the NBE-pGL3P luciferase reporter gene. 40 h post-transfection, cell extracts were made and assayed for luciferase activity.

 

To investigate whether the repression of the NBE-pGL3P luciferase reporter by Nkx3.2 is indeed mediated by direct binding of Nkx3.2 to the NBE sites, the NBE-m1-pGL3P and NBE-m2-pGL3P luciferase reporters, which contain mutant NBE sequences that do not bind to Nkx3.2 (Figs. 2B and 3C), were analyzed in similar reporter assays. Unlike the NBE-pGL3P luciferase reporter, neither the NBE-m1-pGL3P nor the NBE-m2-pGL3P luciferase reporter exhibited any significant repression beyond the intrinsic response of the parental pGL3P luciferase reporter to co-transfected Nkx3.2 (Fig. 4A, compare lanes 2, 6, and 8). These results indicate that Nkx3.2-mediated repression of the NBE-pGL3P luciferase reporter is dependent on Nkx3.2 binding to the NBE sequences.

To further confirm the in vivo interaction between Nkx3.2 and the NBE sequence, we employed Nkx3.2-VP16, in which the strong transcriptional activation domain of HSV-VP16 (30) is fused to the carboxyl terminus of Nkx3.2. Either the pCS2 expression vehicle or pCS2 encoding either Nkx3.2 or Nkx3.2-VP16 was co-transfected into NIH-3T3 cells along with the NBE-pGL3P luciferase reporter. Whereas wild-type Nkx3.2 repressed the expression of the NBE-pGL3P luciferase reporter as expected (Fig. 4B, compare lanes 1 and 2), Nkx3.2-VP16 strongly activated the NBE-pGL3P luciferase reporter (Fig. 4B, compare lanes 1 and 3). These results verify that Nkx3.2 directly binds to NBE sites and regulates transcription in vivo.

Nkx3.2-N200Q Is a DNA Nonbinding Mutant—A large number of homeoproteins have been shown to bind to DNA via their homeodomains and regulate target gene transcription (31, 32). Among the highly conserved amino acids in the homeodomain, a specific asparagine residue (position 51 of the homeodomain), which is part of the recognition helix and makes crucial hydrogen bonds with DNA base pairs during homeodomain/DNA interactions, has been suggested to be essential for the DNA binding activity of various homeoproteins (33, 34). Since a missense mutation of this asparagine to glutamine has been shown to eliminate DNA binding activity in other homeoproteins (35, 36), including those of NK family proteins (37, 38), we attempted to generate a DNA nonbinding mutant of Nkx3.2 (termed Nkx3.2-N200Q) by introducing the same point mutation at the corresponding position (residue 200) of Nkx3.2.

To investigate whether Nkx3.2-N200Q can bind to DNA, bacterially expressed and purified GST-Nkx3.2-N200Q recombinant protein was incubated with 32P-labeled NBE probe and analyzed by EMSA. Purified GST and GST-Nkx3.2 recombinant proteins were also included in the experiment as negative and positive controls, respectively. As expected, the NBE probe failed to interact with the parental GST protein but formed stable complexes with GST-Nkx3.2 (Fig. 5A, lanes 2 and 3). Consistent with previous observations with other homeoproteins (3538), GST-Nkx3.2-N200Q was unable to bind to the NBE probe (Fig. 5A, lane 4). This result not only verifies that Nkx3.2-N200Q is a DNA nonbinding mutant but also suggests that Nkx3.2 binds to DNA in a manner that is structurally similar to that of other homeoproteins (33, 34).



View larger version (36K):
[in this window]
[in a new window]
 
FIG. 5.
Nkx3.2-N200Q is unable to bind to the NBE but retains intrinsic repressor activity. A, purified recombinant GST (lane 2), GST-Nkx3.2-WT (lane 3), or GST-Nkx3.2-N200Q (lane 4) proteins were incubated with 32P-labeled NBE probes and processed for EMSA. B, Nkx3.2-N200Q is unable to repress the NBE reporter. Either the pCS2 expression vector (lane 1), pCS2-Nkx3.2-WT (lane 2), or pCS2-Nkx3.2-N200Q (lane 3) was co-transfected into NIH-3T3 cells along with the NBE-pGL3P luciferase reporter gene. 40 h post-transfection, cell extracts were made and assayed for luciferase activity. C, GAL4-Nkx3.2-N200Q is able to repress the 5x-GAL4 reporter. NIH-3T3 cells were co-transfected with a 5x-GAL4-pGL3E luciferase reporter construct plus expression vehicles encoding the GAL4 DNA binding domain (lane 1), GAL4-Nkx3.2-WT (lane 2), or GAL4-Nkx3.2-N200Q (lane 3). 40 h post-transfection, cell extracts were made and assayed for luciferase activity.

 

Nkx3.2-N200Q Is Unable to Repress the NBE Reporter but Retains Intrinsic Transcriptional Repressor Activity—Since Nkx3.2 represses the NBE reporter by directly binding to the NBE (Fig. 4), we next examined whether the DNA nonbinding Nkx3.2-N200Q mutant can regulate the expression of the NBE-pGL3P luciferase reporter. Either the parental pCS2 expression vehicle or pCS2 encoding either wild-type Nkx3.2 or Nkx3.2-N200Q was co-transfected into NIH-3T3 cells along with the NBE-pGL3P luciferase reporter. In contrast to Nkx3.2-WT (Fig. 5B, lane 2), Nkx3.2-N200Q was unable to repress expression of the NBE-pGL3P luciferase reporter (Fig. 5B, lane 3). Thus, the Nkx3.2-N200Q mutant has lost its ability to repress the NBE reporter, most likely due to its inability to bind DNA.

To confirm that the inability of Nkx3.2-N200Q to repress the NBE reporter is due to a specific defect in DNA binding, we evaluated the transcriptional repressor activity of Nkx3.2-N200Q when fused to the DNA binding domain of GAL4 (GAL4-Nkx3.2-N200Q). A 5x-GAL4-pGL3E luciferase reporter, which contains five GAL4 binding sites and the E1b TATA box 5' to the luciferase gene and the SV40 enhancer 3' to the gene (20), was transfected into NIH-3T3 cells in the presence of an expression vehicle encoding either the GAL4 DNA binding domain, GAL4-Nkx3.2-WT, or GAL4-Nkx3.2-N200Q. Consistent with our prior findings (10), transfection of GAL4-Nkx3.2-WT significantly repressed the expression of the 5x-GAL4-pGL3E luciferase reporter (Fig. 5C, lane 2). Interestingly, GAL4-Nkx3.2-N200Q similarly displayed efficient transcriptional repressor activity (Fig. 5C, lane 3), indicating that the N200Q missense mutation introduced into the homeodomain of Nkx3.2 altered only its DNA binding activity without compromising its intrinsic transcriptional repressor activity.

The DNA Binding Activity of Nkx3.2 Is Required to Induce Somitic Chondrogenesis—Prior work has indicated that Nkx3.2 function as a transcriptional repressor to promote somitic chondrogenesis (8, 10) However, it has not been characterized whether this activity of Nkx3.2 is dependent on direct binding to DNA. Since Nkx3.2-N200Q is specifically defective in its DNA binding (Fig. 5, A and B) but not in its intrinsic transcriptional repressor activity (Fig. 5C), we sought to evaluate whether Nkx3.2-N200Q would be competent to induce somitic chondrogenesis. Explants of psm dissected from Hamburger and Hamilton stage 10 chick embryos were infected with nondefective avian retroviruses (RCAS) (21) encoding either GFP, Nkx3.2-WT, or Nkx3.2-N200Q and cultured in the presence of BMP signals. After 6 days in culture, the explants were harvested, and expression of chondrogenic differentiation markers such as aggrecan, epiphycan, collagen IX, and Sox9 (Fig. 6, B–E, respectively) was analyzed by RT-PCR as previously described (8, 10). Glyceraldehyde-3-phosphate dehydrogenase expression was also analyzed in these various cultures as a control for explant viability (Fig. 6A). As expected, forced expression of Nkx3.2-WT induced robust expression of the chondrogenic marker genes in the psm explant cultures (Fig. 6, lane 2). Whereas Nkx3.2-WT and Nkx3.2-N200Q were expressed at equivalent levels (Fig. 6F), overexpression of Nkx3.2-N200Q, which is unable to bind to DNA (Fig. 5A) but retains its transcriptional repressor activity (Fig. 5C), failed to significantly activate the chondrocyte differentiation program (Fig. 6, lane 3). These results indicate that the DNA binding activity of Nkx3.2 is essential for this factor to promote the chondrocyte differentiation program in somitic tissue.



View larger version (60K):
[in this window]
[in a new window]
 
FIG. 6.
The DNA binding activity of Nkx3.2 is essential for induction of somitic chondrogenesis. psm were dissected from Hamburger and Hamilton stage 10 chick embryos, cultured in vitro, and infected with the following avian retroviruses: RCAS-GFP (lane 1), RCAS-Nkx3.2-WT (lane 2), or RCAS-Nkx3.2-N200Q (lane 3). After 2 days of culture, BMP4 (100 ng/ml) was added to the explants. After 6 days of culture in total, the explants were harvested, and expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (A), aggrecan (B), epiphycan (C), collagen IX (D), Sox9 (E), and viral encoded Nkx3.2 transcript (F) was assayed by RT-PCR.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Identification of Nkx3.2 DNA Binding Sequences—In this report, we have identified TAAGTG as an NBE by using the CAST technique. The sequence AGT, found in the core region of all oligonucleotides selected to bind to Nkx3.2 (Fig. 1), is likely to be an essential core motif necessary for interaction with Nkx3.2. Indeed, Nkx3.2 fails to bind to DNA sequences containing mutations disrupting this AGT motif (Figs. 2B and 3C). The TAAGTG consensus binding sequence has not been reported for other NK family homeoproteins. However, it is quite similar to previously characterized high affinity DNA binding sites for other NK class homeoproteins such as CAAGTG for Nkx2.1 (28), TAAGTA for Nkx3.1 (22), TNAAGTG for Nkx2.5 (23), and AAAGTG for ceh-22, the Caenorhabditis elegans NK-2 homologue (39). Interestingly, we have found that Nkx3.2 can also bind to various NBE related sequences in vitro by EMSA assays (Fig. 3). Furthermore, we have shown that expression of a reporter gene containing reiterated NBE sites can be repressed by co-transfected Nkx3.2 in vivo (Fig. 4). Together, these results suggest that the NBE and/or NBE-related sequences may serve as Nkx3.2 binding sites that mediate Nkx3.2-dependent transcriptional repression in vivo.

Structural Basis of Nkx3.2 DNA Binding Is Very Similar to That of Other Previously Characterized Homeoproteins—A large number of homeoproteins including NK family members contain a highly conserved asparagine residue in the third helix of the homeodomain (33, 34). Nkx3.2 also contains this conserved asparagine at residue 200. Similar to other previously characterized homeoproteins (3538), an asparagine to glutamine substitution at this position of Nkx3.2 eliminated its ability to bind to the NBE sequence (Fig. 5, A and B). Furthermore, we have also found that an adenine base at the third position of the NBE is essential for interaction with Nkx3.2 (Fig. 3D). This invariant adenine base at the third position of homeodomain binding sites has been shown to make a crucial contact with the highly conserved asparagine residue in the third helix of the homeodomain (33, 34). Together these findings strongly suggest that Nkx3.2 binds to DNA in a manner that is structurally very similar to other previously characterized homeodomain-containing proteins.

It is currently unclear whether Nkx3.2 binds to DNA as a monomer or dimer (or multimer). However, several lines of evidence suggest that Nkx3.2 may bind to DNA as a monomer. First, none of the sequences selected by Nkx3.2 in the CAST technique displayed any apparent palindromic or repetitive sequence pattern, which frequently is observed in the binding sites for dimeric (or multimeric) proteins (26, 40, 41). Instead, Nkx3.2 binds to a nonpalindromic hexanucleotide sequence motif. Second, we have found that the DNA binding characteristics of Nkx3.2 resemble those of other well characterized homeodomain-containing proteins, which have been shown to make intimate contacts with the DNA via the helix-turn-helix motif of the homeodomain as a monomer (33, 34). Therefore, it seems most likely that Nkx3.2 similarly binds to its target sequences as a monomer. However, it is certainly possible that association of Nkx3.2 with other proteins in vivo may alter the DNA binding specificity of Nkx3.2 and thereby target it to sites other than simple NBE sequences.

Nkx3.2 Promotes Somitic Chondrogenesis via Its Direct Binding to DNA—We demonstrated that a DNA nonbinding mutant form of Nkx3.2, Nkx3.2-N200Q, failed to activate the chondrocyte differentiation program in presomitic mesoderm explant cultures (Fig. 6), indicating that Nkx3.2 must directly bind to DNA to promote somitic chondrogenesis. Since we have found that the intrinsic transcriptional repressor activity of Nkx3.2-N200Q remains intact (Fig. 5C), it seems most likely that Nkx3.2-N200Q fails to induce somitic chondrogenesis due to its specific inability to recognize its target genes. The dependence of Nkx3.2 prochondrogenic activity on DNA binding is of importance, since it has been shown that a number of transcriptional regulators can execute their biological activity via protein-protein interactions with transcriptional partners in the absence of direct DNA binding (4246).

Nkx3.2 Activates Chondrogenesis by Repressing Antichondrogenic Genes—It has been previously been shown that BMP signals can antagonize sclerotomal gene expression in paraxial mesoderm and elicit the expression of lateral plate mesodermal markers such as GATA-4, -5, and -6 (9, 4749).2 However, after prior exposure to Shh, paraxial mesodermal cells interpret subsequent BMP signals as prochondrogenic cues (9). In this case, BMP signals strongly promote somitic chondrogenesis, and the induction of GATA family members by BMP signaling is blocked (9). Thus, Shh signaling alters the cellular response of paraxial mesodermal cells to subsequent BMP signals. Since Nkx3.2 is a transcriptional repressor induced by Shh in somitic mesoderm (8, 10), it may play an important role in preserving a prochondrogenic cellular environment by repressing an antichondrogenic gene(s) upon exposure to secondary BMP signaling. We have previously shown that Shh can induce Nkx3.2 in somitic mesoderm and that forced expression of Nkx3.2 in somites induces the expression of Sox9, which can in turn activates the chondrogenic differentiation program in somitic mesodermal cells (8, 10). Therefore, our current hypothesis is that Nkx3.2 induces somitic chondrogenesis by repressing the expression of an antichondrogenic gene(s) that blocks the expression or function of various prochondrogenic genes such as Sox family proteins (5057).

The findings of the present study indicate that the prochondrogenic activity of Nkx3.2 requires direct DNA binding by this transcription factor and suggest that antichondrogenic gene(s) repressed by Nkx3.2 should contain NBE-like sequences regulating their expression. Interestingly, we have found that forced expression of Nkx3.2 in somitic tissue will block the induction of GATA-4, -5, and -6 by BMP signals and that repression of GATA-6 expression by Nkx3.2 requires an NBE-like sequence in the GATA-6 promoter.3 Thus, members of the GATA gene family are potential direct targets of Nkx3.2 in vivo and therefore could potentially play a role in modulating chondrogenesis. Present work in our laboratory is focused on determining whether GATA family members or other targets of Nkx3.2 are negative regulators of chondrogenesis.


    FOOTNOTES
 
* This work was funded by grants from the National Institutes of Health (to A. B. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} Supported by a fellowship from the Arthritis Foundation. Back

§ Supported by a fellowship from ARC and a long-term fellowship from the Human Frontier Science Program and a recipient of a Fondation Bettencourt Schueller award. Back

To whom correspondence should be addressed: Dept. of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115. Tel.: 617-432-3831; Fax: 617-738-0516; E-mail: andrew_lassar{at}hms.harvard.edu.

1 The abbreviations used are: Shh, Sonic Hedgehog; BMP, bone morphogenetic protein; EMSA, electrophoretic mobility shift assay; psm, presomitic mesoderm; HA, hemagglutinin; GST, glutathione S-transferase. Back

2 D.-W. Kim, H. Kempf, R. E. Chen, and A. B. Lassar, unpublished data. Back

3 H. Kempf, D.-W. Kim, and A. B. Lassar, manuscript in preparation. Back


    ACKNOWLEDGMENTS
 
We thank Dr. Cliff Tabin for providing the RCAS-GFP construct and Genetics Institute for kindly supplying recombinant human BMP4 protein. We thank former and current members of the Lassar laboratory for helpful discussions and especially L. C. Murtaugh for previously generated reagents.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Huang, R., Zhi, Q., Schmidt, C., Wilting, J., Brand-Saberi, B., and Christ, B. (2000) Development 127, 527–532[Abstract/Free Full Text]
  2. Hirsinger, E., Jouve, C., Dubrulle, J., and Pourquie, O. (2000) Int. Rev. Cytol. 198, 1–65[Medline] [Order article via Infotrieve]
  3. Stockdale, F. E., Nikovits, W., Jr., and Christ, B. (2000) Dev. Dyn. 219, 304–321[CrossRef][Medline] [Order article via Infotrieve]
  4. Dockter, J. L. (2000) Curr. Top. Dev. Biol. 48, 77–127[Medline] [Order article via Infotrieve]
  5. Britto, J. M., Tannahill, D., and Keynes, R. J. (2000) Bioessays 22, 499–502[CrossRef][Medline] [Order article via Infotrieve]
  6. Johnson, R. L., Laufer, E., Riddle, R. D., and Tabin, C. (1994) Cell 79, 1165–1173[Medline] [Order article via Infotrieve]
  7. Teillet, M., Watanabe, Y., Jeffs, P., Duprez, D., Lapointe, F., and Le Douarin, N. M. (1998) Development 125, 2019–2030[Abstract/Free Full Text]
  8. Zeng, L., Kempf, H., Murtaugh, L. C., Sato, M. E., and Lassar, A. B. (2002) Genes Dev. 16, 1990–2005[Abstract/Free Full Text]
  9. Murtaugh, L. C., Chyung, J. H., and Lassar, A. B. (1999) Genes Dev. 13, 225–237[Abstract/Free Full Text]
  10. Murtaugh, L. C., Zeng, L., Chyung, J. H., and Lassar, A. B. (2001) Dev. Cell 1, 411–422[Medline] [Order article via Infotrieve]
  11. Kawakami, Y., Ishikawa, T., Shimabara, M., Tanda, N., Enomoto-Iwamoto, M., Iwamoto, M., Kuwana, T., Ueki, A., Noji, S., and Nohno, T. (1996) Development 122, 3557–3566[Abstract/Free Full Text]
  12. Kim, Y., and Nirenberg, M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7716–7720[Abstract]
  13. Harvey, R. P. (1996) Dev. Biol. 178, 203–216[CrossRef][Medline] [Order article via Infotrieve]
  14. Tribioli, C., Frasch, M., and Lufkin, T. (1997) Mech. Dev. 65, 145–162[CrossRef][Medline] [Order article via Infotrieve]
  15. Tribioli, C., and Lufkin, T. (1999) Development 126, 5699–5711[Abstract/Free Full Text]
  16. Lettice, L. A., Purdie, L. A., Carlson, G. J., Kilanowski, F., Dorin, J., and Hill, R. E. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9695–9700[Abstract/Free Full Text]
  17. Akazawa, H., Komuro, I., Sugitani, Y., Yazaki, Y., Nagai, R., and Noda, T. (2000) Genes Cells 5, 499–513[Abstract/Free Full Text]
  18. Riddle, R. D., Johnson, R. L., Laufer, E., and Tabin, C. (1993) Cell 75, 1401–1416[Medline] [Order article via Infotrieve]
  19. Sadowski, I., and Ptashne, M. (1989) Nucleic Acids Res. 17, 7539[Medline] [Order article via Infotrieve]
  20. Denisenko, O. N., and Bomsztyk, K. (1997) Mol. Cell. Biol. 17, 4707–4717[Abstract]
  21. Hughes, S. H., Greenhouse, J. J., Petropoulos, C. J., and Sutrave, P. (1987) J. Virol. 61, 3004–3012[Medline] [Order article via Infotrieve]
  22. Steadman, D. J., Giuffrida, D., and Gelmann, E. P. (2000) Nucleic Acids Res. 28, 2389–2395[Abstract/Free Full Text]
  23. Chen, C. Y., and Schwartz, R. J. (1995) J. Biol. Chem. 270, 15628–15633[Abstract/Free Full Text]
  24. Morgan, B. A., and Fekete, D. M. (1996) Methods Cell Biol. 51, 185–218[Medline] [Order article via Infotrieve]
  25. Blackwell, T. K. (1995) Methods Enzymol. 254, 604–618[Medline] [Order article via Infotrieve]
  26. Blackwell, T. K., Kretzner, L., Blackwood, E. M., Eisenman, R. N., and Weintraub, H. (1990) Science 250, 1149–1151[Medline] [Order article via Infotrieve]
  27. Amendt, B. A., Sutherland, L. B., and Russo, A. F. (1999) J. Biol. Chem. 274, 11635–11642[Abstract/Free Full Text]
  28. Guazzi, S., Price, M., De Felice, M., Damante, G., Mattei, M. G., and Di Lauro, R. (1990) EMBO J. 9, 3631–3639[Abstract]
  29. Catron, K. M., Iler, N., and Abate, C. (1993) Mol. Cell. Biol. 13, 2354–2365[Abstract]
  30. Sadowski, I., Ma, J., Triezenberg, S., and Ptashne, M. (1988) Nature 335, 563–564[CrossRef][Medline] [Order article via Infotrieve]
  31. McGinnis, W., and Krumlauf, R. (1992) Cell 68, 283–302[Medline] [Order article via Infotrieve]
  32. Krumlauf, R. (1994) Cell 78, 191–201[Medline] [Order article via Infotrieve]
  33. Kissinger, C. R., Liu, B. S., Martin-Blanco, E., Kornberg, T. B., and Pabo, C. O. (1990) Cell 63, 579–590[Medline] [Order article via Infotrieve]
  34. Fraenkel, E., and Pabo, C. O. (1998) Nat. Struct. Biol. 5, 692–697[CrossRef][Medline] [Order article via Infotrieve]
  35. Botfield, M. C., Jancso, A., and Weiss, M. A. (1994) Biochemistry 33, 6177–6185[Medline] [Order article via Infotrieve]
  36. Pomerantz, J. L., and Sharp, P. A. (1994) Biochemistry 33, 10851–10858[Medline] [Order article via Infotrieve]
  37. Choi, C. Y., Kim, Y. H., Kwon, H. J., and Kim, Y. (1999) J. Biol. Chem. 274, 33194–33197[Abstract/Free Full Text]
  38. Choi, C. Y., Lee, Y. M., Kim, Y. H., Park, T., Jeon, B. H., Schulz, R. A., and Kim, Y. (1999) J. Biol. Chem. 274, 31543–31552[Abstract/Free Full Text]
  39. Harfe, B. D., and Fire, A. (1998) Development 125, 421–429[Abstract/Free Full Text]
  40. Blackwell, T. K., and Weintraub, H. (1990) Science 250, 1104–1110[Medline] [Order article via Infotrieve]
  41. Blackwell, T. K., Huang, J., Ma, A., Kretzner, L., Alt, F. W., Eisenman, R. N., and Weintraub, H. (1993) Mol. Cell. Biol. 13, 5216–5224[Abstract]
  42. Laherty, C. D., Yang, W. M., Sun, J. M., Davie, J. R., Seto, E., and Eisenman, R. N. (1997) Cell 89, 349–356[Medline] [Order article via Infotrieve]
  43. Wotton, D., Lo, R. S., Swaby, L. A., and Massague, J. (1999) J. Biol. Chem. 274, 37105–37110[Abstract/Free Full Text]
  44. Janknecht, R., Wells, N. J., and Hunter, T. (1998) Genes Dev. 12, 2114–2119[Abstract/Free Full Text]
  45. Wotton, D., Lo, R. S., Lee, S., and Massague, J. (1999) Cell 97, 29–39[Medline] [Order article via Infotrieve]
  46. Neuhold, L. A., and Wold, B. (1993) Cell 74, 1033–1042[Medline] [Order article via Infotrieve]
  47. Reshef, R., Maroto, M., and Lassar, A. B. (1998) Genes Dev. 12, 290–303[Abstract/Free Full Text]
  48. Tonegawa, A., Funayama, N., Ueno, N., and Takahashi, Y. (1997) Development 124, 1975–1984[Abstract/Free Full Text]
  49. Hirsinger, E., Duprez, D., Jouve, C., Malapert, P., Cooke, J., and Pourquie, O. (1997) Development 124, 4605–4614[Abstract/Free Full Text]
  50. Sekiya, I., Tsuji, K., Koopman, P., Watanabe, H., Yamada, Y., Shinomiya, K., Nifuji, A., and Noda, M. (2000) J. Biol. Chem. 275, 10738–10744[Abstract/Free Full Text]
  51. Ng, L. J., Wheatley, S., Muscat, G. E., Conway-Campbell, J., Bowles, J., Wright, E., Bell, D. M., Tam, P. P., Cheah, K. S., and Koopman, P. (1997) Dev. Biol. 183, 108–121[CrossRef][Medline] [Order article via Infotrieve]
  52. Lefebvre, V., Huang, W., Harley, V. R., Goodfellow, P. N., and de Crombrugghe, B. (1997) Mol. Cell. Biol. 17, 2336–2346[Abstract]
  53. Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrugghe, B. (1999) Nat. Genet. 22, 85–89[CrossRef][Medline] [Order article via Infotrieve]
  54. Bi, W., Huang, W., Whitworth, D. J., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrugghe, B. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 6698–6703[Abstract/Free Full Text]
  55. Lefebvre, V., Li, P., and de Crombrugghe, B. (1998) EMBO J. 17, 5718–5733[Abstract/Free Full Text]
  56. Smits, P., Li, P., Mandel, J., Zhang, Z., Deng, J. M., Behringer, R., de Crombrugghe, B., and Lefebvre, V. (2001) Dev. Cell 1, 277–290[Medline] [Order article via Infotrieve]
  57. Akiyama, H., Chaboissier, M. C., Martin, J. F., Schedl, A., and De Crombrugghe, B. (2002) Genes Dev. 16, 2813–2828[Abstract/Free Full Text]